Development of a novel prognostic score for breast cancer patients using mRNA expression of CHAC1. (October 2017)

• Record Type: Journal Article
• Authors: Jahn, Beate; Arvandi, Marjan; Rochau, Ursula; Fiegl, Heidi; Goebel, Georg; Marth, Christian; Siebert, Uwe
• Is Part Of: Journal of comparative effectiveness research. Volume 6:Number 7(2017)
• Page Start: 563
• Page End: 574
• Publication Date: 2017-10
• Subjects: adjuvant chemotherapy -- biomarker -- breast cancer -- CHAC1 mRNA -- decision aid -- prognostic score; Medical care -- Research -- Periodicals; Medical care -- Research -- Evaluation -- Periodicals; Medical care -- Decision making -- Periodicals; Evidence-based medicine -- Periodicals; Medicine, Comparative -- Periodicals; 362.1072
• DOI: 10.2217/cer-2017-0015
• Languages: English
• ISSNs: 2042-6305

Abstract

Aim: To develop a prognostic score for primary breast cancer patients integrating conventional predictors and the novel biomarker CHAC1 to aid adjuvant chemotherapy decisions.Patients & methods: A prognostic score for overall survival was developed using: conventional predictors from a dataset of 1777 patients and the weight of CHAC1 mRNA expression from an independent dataset of 106 patients using multivariate Cox regression.Results: The new score includes: CHAC1 mRNA expression, age, tumor size, HER2 neu status, lymph node status and degree of malignancy. Using a cut-off value of 11 score points, 10-year survival was 82% in low-risk (n = 34) and 43% in high-risk patients (n = 72). The addition of CHAC1 resulted in 16% reclassification.Conclusion: Including CHAC1 in prognostic prediction may aid (and change) personalized treatment selection.